The global lymphoma treatment market size is expected to
reach USD 26.4 billion by 2026, according to a new report by Grand View
Research, Inc., exhibiting a CAGR of 9.5%. Rising research activities for
development of new treatments and increasing product line extension are likely
to expedite growth. Increasing commercialization of novel drugs are further
expected to drive the growth.
Availability of wide variety of products is
further expected to aid growth. For instance, in January 2019, BeiGene received
a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib
for treating mantle cell lymphoma in adults. This drug is currently in
late-stage clinical trial and is expected to be launched during the forecast
period.
Growing awareness about early diagnosis of
lymphoma among healthcare professionals & patients and rising government
funding for R&D are some factors expected to propel market growth. For
instance, institutes such as National Cancer Institute receives funding from
the U.S. Congress to support cancer-related research and associated activities.
Browse full research report on Lymphoma
Treatment Market: https://www.grandviewresearch.com/industry-analysis/lymphoma-market
Further key
findings from the report suggest:
- Non-Hodgkin lymphoma held the largest share in
2018 owing to prevalence of non-Hodgkin lymphoma and presence of
blockbuster drugs.
- Hodgkin lymphoma is expected to be the fastest
growing segment due to presence of strong product pipeline and increase in
the number of label extension for existing drugs.
- Based on drug, Revlimid held the highest share
in 2018 and is expected to grow at a significant rate during the forecast
period. This can be attributed to growing use of this product in cancer
treatment regimens.
- Rituxan/MabThera held the second largest share
in 2018 owing to increasing use of this product in multiple indications
and high prescription rate in major markets such as the U.S., Europe, and
Japan.
- North America dominated in 2018, followed by
Europe. This can be attributed to well-established healthcare
infrastructure, high R&D expenditure, availability of novel drugs, and
presence of key players.
- Asia Pacific is expected to be the fastest
growing over the forecast period owing to increase in commercialization of
products, rise in awareness about diseases and high unmet clinical needs.
- Some of the major players are Celgene
Corporation; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.;
Seattle Genetics, Inc.; Merck & Co., Inc.; Johnson & Johnson;
Takeda Pharmaceutical Company Ltd.; Abbott Laboratories; and Eli Lilly and
Company.
- Key players for lymphoma treatment market are
adopting strategies such as collaborations, mergers & acquisitions,
product development, product line extension, and regional expansion to
increase their share. For instance, Seattle Genetics collaborated with
Takeda Pharmaceuticals for commercialization of Adcetris in different
regions other than North America.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/lymphoma-market/request/rs1
Grand
View Research has segmented the global lymphoma treatment market on the basis
of type, drug, and region:
Lymphoma
Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
Lymphoma
Treatment Drug Outlook (Revenue, USD Million, 2015 - 2026)
- Adcetris
- Opdivo
- Rituxan/MabThera
- Imbruvica
- Keytruda
- Revlimid
- Others
Lymphoma
Treatment Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- UAE
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment